前列腺癌组织中泛素偶联酶E2C、蛋白激酶B表达及其与预后相关性

Expression of ubiquitin-conjugating enzyme E2C and protein kinase B in prostate cancer and its correlation with prognosis

目的探讨前列腺癌组织中泛素偶联酶E2C(UBE2C)、蛋白激酶B(AKT1)表达及其预后相关性。方法选取2014年1月至2016年12月四川大学华西医院泌尿外科研究所收集的92例前列腺癌组织(前列腺癌组)、70例良性前列腺增生组织(良性前列腺增生组)进行研究,根据随访结果将前列腺癌组分为两组,预后良好组(68例)、预后不良组(24例)。采用免疫组织化学法检测不同组织中UBE2C、AKT1表达情况进行比较,并分析其与病人临床病理特征关系;采用COX回归模型分析前列腺癌病人预后影响因素。结果与良性前列腺增生组相比,前列腺癌组UBE2C[84.78%(78/92)比22.86%(16/70)]、AKT1[78.26%(72/92)比28.57%(20/70)]阳性表达率均较高(P<0.05);前列腺癌组UBE2C表达与年龄、TNM分期、术前前列腺特异抗原(PSA)水平均无关(P>0.05),与Gleason评分、淋巴结转移均有关(P<0.05),AKT1表达与年龄、淋巴结转移无关(P>0.05),与Gleason评分、TNM分期、术前PSA水平均有关(P<0.05);与预后良好组相比,预后不良组UBE2C[100.00%(100/100)比79.41%(54/68)]、AKT1[95.83%(23/100)比72.06%(49/68)]阳性表达率均较高(P<0.05);COX回归模型分析结果显示,Gleason评分≥7分、Ⅲ/Ⅳ期、伴淋巴结转移、术前PSA水平>10µg/L、UBE2C高表达、AKT1高表达均是影响前列腺癌病人预后状况的独立危险因素(P<0.05)。结论前列腺癌病人病灶组织UBE2C、AKT1均为高表达,且与病人临床病理特征及预后状况密切相关,可能为评估病情及预后提供临床参考依据。

Objective To investigate the expression of ubiquitin-conjugating enzyme E2C(UBE2C)and protein kinase B(AKT1)in prostate cancer tissues and their correlation with prognosis.Methods A total of 92 cases of prostate cancer(prostate cancer group)and 70 cases of benign prostate hyperplasia(benign prostate hyperplasia group)collected from January 2014 to December 2016 at the Institute of Urology,West China Hospital,Sichuan University were selected for study.According to the follow-up results,the prostate cancer group was divided into two groups,the good prognosis group(68 cases)and the poor prognosis group(24 cases).The expression of UBE2C and AKT1 in different groups of tissues was detected by immunohistochemistry,and the relationship between them and the clinicopathological characteristics of the patients was analyzed.The Cox regression model was used to analyze the prognostic factors of prostate cancer patients.Results Compared with the benign prostate hyperplasia group,the positive rates of UBE2C[84.78%(78/92)vs.22.86%(16/70)]and AKT1[78.26%(72/92)vs.28.57%(20/70)]in the prostate cancer group were higher(P<0.05).In prostate cancer group,the expression of UBE2C was not related to age,tumor node metastasis(TNM)stage or preoperative prostate-specific antigen(PSA)level(P>0.05)but was related to Gleason score and lymph node metastasis(P<0.05).The expression of AKT1 in the prostate cancer group was not related to age or lymph node metastasis(P>0.05),but was related to Gleason score,TNM stage and preoperative PSA level(P<0.05).The positive rates of UBE2C[100.00%(100/100)vs.79.41%(54/68)]and AKT1[95.83%(23/100)vs.72.06%(49/68)]in the poor prognosis group were higher than those in the good prognosis group(P<0.05).The results of Cox regression model analysis showed that Gleason score≥7,stageⅢ/Ⅳ,with lymph node metastasis,preoperative PSA level>10µg/L,and high expression of UBE2C and AKT1 were all independent risk factors for the prognosis of patients with prostate cancer(P<0.05).Conclusion UBE2C and AKT1 are highly expressed in the lesions of prostate cancer patients and are closely related to the clinicopathological characteristics and prognosis of patients,which may provide a clinical reference for the evaluation of the disease and prognosis.